Zydus Cadila gets USFDA nod for Desvenlafaxine Extended-Release Tablets

12 Oct 2017 Evaluate

Zydus Cadila has received the final approval from the U.S. Food & Drug Administration (USFDA) to market Desvenlafaxine Extended-Release Tablets, 50 mg and 100 mg. The drug is used to treat major depression and will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

 

Zydus Lifesciences Share Price

885.20 -20.80 (-2.30%)
16-Mar-2026 11:58 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1774.80
Dr. Reddys Lab 1266.60
Cipla 1298.00
Zydus Lifesciences 885.20
Lupin 2280.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×